Dr. Wheelock joined the faculty at UC Davis in 1996 and launched the Movement Disorders program. She started the Huntington's disease clinic at UC Davis, and the clinic was designated a Center of Excellence by the Huntington's Disease Society of America (HDSA) in 2001. Dr. Wheelock also co-directed a satellite program for the surgical treatment of Parkinson's disease through Kaiser Permanente from 1998-2006 and has extensive experience in Deep Brain Stimulator therapy. She has also been active with HDSA, serving on the Center Program and Education Advisory Committee since 2004, and she received the HDSA Patient and Family Care Award in 2007. A member of the Huntington Study Group (HSG) since 1997, Dr. Wheelock has served as a site investigator for numerous HSGsponsored trials, and was elected to the Executive Committee in 2007. Dr. Wheelock has recently formed a collaboration with Dr. Jan Nolta in the UC Davis Center for Regenerative Medicine with the goal of developing stem cell therapies for Huntington's disease.
M.D., University of Michigan Medical School, Ann Arbor, Michigan, 1983
B.S., University of Michigan, Ann Arbor, Michigan, 1979
University of Southern California, Los Angeles, California, 1984-1987
American Board of Psychiatry and Neurology, 1990
National Board of Medical Examiners, 1984
American Academy of Neurology
Dystonia Medical Research Foundation
Huntington Study Group
Huntington?s Disease Society of America
International Tremor Foundation
Movement Disorder Society
Select Recent Publications
Higginson CI, Wheelock V, Levine D, King D, Pappas CTEand Sigvardt KA. Cognitive Deficits in Essential Tremor Consistent with Frontosubcortical Dysfunction, J Clin Exp Neuropsychol. 2008 Feb 15:1-6.
Higginson CI, Wheelock V, Levine D, King D, Pappas CTEand Sigvardt KA. The clinical significance of neuropsychological changes following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. J C1in Exp Neuropsychol. 2008 May 19:1-8.
Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008 Dec;65(12):1582-9.
Paulsen JS, Hayden M, Stout JCand the PREDICT-HD Investigators. Preparing for clinical trials: The PREDICT-HDstudy. Arch Neurol 2006;63:883-890
Shoulson I and the Huntington Study Group PHAROS Investigators. At Risk for Huntington Disease: The PHAROS(Prospective Huntington At Risk Observational Study) Cohort Enrolled. Arch Neurol 2006;63:991-998.
Wheelock VL, Tempkin T, Marder K, Nance M, Myers R, Zhao H, Kayson E, Orme C, Shoulson I and the Huntington Study Group. Predictors of nursing home placement in Huntington disease. Neurology 60:998-1001, 2003.